The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Vibegron (Obgemsa®) has been accepted for use in the symptomatic treatment of adult patients with overactive bladder (OAB) syndrome. It is noted that this treatment offers an additional choice in the therapeutic class of beta-3 adrenergic receptor agonists.
Levodopa / carbidopa / entacapone intestinal gel (Lecigon®) has been rejected for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results. The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.